Screener
Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Income Tax Expense Benefit
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Three Months Ended June 30, | Six Months Ended June 30, |
|---|---|---|
| Other expense, net | (488)) | (301)) |
| Change in fair value of warrant liability | 212 | 2,467 |
| (Loss) Income before income taxes | (1,575)) | 4,265) |
| Benefit (provision) for income taxes | (662) | (1,563)) |
| Net (loss) income | (2,237)) | 2,702) |
| Accretion of Cullgen redeemable convertible preferred stock | (2,642)) | (5,220)) |
| Net loss attributable to noncontrolling interest | (2,835)) | (2,644)) |
| Net (loss) income attributable to common stockholders | $$(2,044)) | $$126) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — income tax expense benefit?
- Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — income tax expense benefit of -$165K in Q2 2026.
- How has Gyre Therapeutics, Inc.'s gyre pharmaceuticals — income tax expense benefit changed year-over-year?
- Gyre Therapeutics, Inc.'s gyre pharmaceuticals — income tax expense benefit decreased by 124.9% year-over-year, from $662K to -$165K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s gyre pharmaceuticals — income tax expense benefit?
- Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s gyre pharmaceuticals — income tax expense benefit has grown at a -26.8% compound annual growth rate (CAGR), from $8.51M to $4.55M.
- What does gyre pharmaceuticals — income tax expense benefit mean?
- This represents the total income tax provision or benefit allocated to the specific business segment. It reflects the tax impact of the segment's operations based on applicable jurisdictional tax rates and accounting standards. Investors use this to understand the net impact of taxation on the segment's bottom-line profitability.
Ask your AI about Gyre Therapeutics, Inc.'s gyre pharmaceuticals — income tax expense benefit.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude